Metagenomi, Inc. 2023 Form 10-K Summary
Business context and reporting period
Metagenomi is an early-stage precision genetic medicines company developing genome-editing therapeutics using a metagenomics-derived platform. Its toolbox includes programmable nucleases, base editors, RNA-mediated integration systems and CRISPR-associated transposases. The filing covers the year ended December 31, 2023. All programs remained preclinical; the company had not initiated IND-enabling studies or clinical development and had no approved products or product sales.
The company completed a corporate reorganization on January 24, 2024, followed by a 1-for-1.74692 reverse stock split and an initial public offering in February 2024. Common stock began trading on Nasdaq under the symbol MGX on February 9, 2024.
Financial performance, liquidity and capital structure
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Collaboration revenue | $44.8 million | $17.2 million | +$27.6 million |
| Research and development expense | $94.4 million | $43.1 million | +$51.3 million |
| General and administrative expense | $28.8 million | $18.7 million | +$10.1 million |
| Loss from operations | $(78.5) million | $(44.6) million | $(33.9) million |
| Net loss | $(68.3) million | $(43.6) million | $(24.7) million |
| Interest income | $15.5 million | $3.4 million | +$12.0 million |
| Income tax expense | $8.0 million | $2.6 million | +$5.5 million |
| Net cash used in operating activities | $(91.4) million | $29.7 million provided | $(121.1) million |
Revenue was entirely collaboration revenue: Ionis contributed $21.9 million, Moderna $18.1 million and Affini-T $4.7 million. The company generated no product revenue. The implied operating margin was approximately negative 175% and the net margin approximately negative 153% in 2023.
At December 31, 2023, cash and cash equivalents were $140.6 million, available-for-sale marketable securities were $130.6 million and restricted cash was $5.2 million. Total assets were $364.8 million and total liabilities were $149.7 million. The filing does not disclose conventional interest-bearing debt outstanding at year-end; operating lease liabilities totaled $48.2 million, with approximately $71.0 million of undiscounted future lease payments.
Cash used in operations increased materially as the company expanded research activities and recognized collaboration revenue from previously received upfront payments. Investing cash flow was positive $45.7 million, primarily reflecting marketable-security maturities exceeding purchases. Financing cash flow was $1.0 million, including $4.3 million of net preferred-unit proceeds and $3.3 million of IPO costs.
In February 2024, the IPO generated $93.8 million of gross proceeds and approximately $81.1 million of net proceeds. Management stated that year-end liquidity plus IPO proceeds should fund the current operating plan into 2027, although the estimate depends on assumptions that may prove incorrect and additional financing is expected to be required.
Material changes versus the prior comparable period
- Collaboration revenue increased 160%, primarily because the Ionis agreement progressed from $0.1 million of revenue in 2022 to $21.9 million in 2023.
- Research and development expense more than doubled, driven by increased personnel, laboratory supplies, facilities, manufacturing investment and external preclinical work.
- General and administrative expense increased 54%, reflecting expanded staffing, professional services and preparation for public-company operations.
- Net loss increased 57% despite higher collaboration revenue and interest income.
- Operating cash flow changed from $29.7 million provided in 2022 to $91.4 million used in 2023, largely because 2022 benefited from the $80.0 million Ionis upfront payment while 2023 reduced deferred revenue as services were performed.
- Unit-based compensation increased to $6.9 million from $2.0 million. A July 2023 amendment to the profits-interest plan created a catch-up feature and resulted in an estimated $10.3 million modification expense, of which $1.2 million was recognized in 2023 and $7.8 million remained to be recognized over approximately 2.8 years.
- Property and equipment increased to $21.5 million from $16.5 million, consistent with laboratory and manufacturing investment. The company also entered into a significant new facility sublease commencing in January 2023.
Pipeline, outlook, commentary and risks
The lead programs were Hemophilia A, PH1 and transthyretin amyloidosis. Hemophilia A showed preclinical proof-of-concept in mice and non-human primates, including mean FVIII activity of 13% to 75% of normal in three NHPs over days 14 to 126. The company planned a second NHP study and development-candidate selection by mid-2024. The PH1 program achieved disease-model proof-of-concept with Moderna and was expected to generate NHP data in 2024. The TTR program, partnered with Ionis, achieved 88% to 98% protein knockdown in a humanized mouse model and was expected to enter NHP studies in 2024.
Additional discovery-stage programs include angiotensinogen, A1AT deficiency, Wilson’s disease, ALS, CMT1a, Duchenne muscular dystrophy, cystic fibrosis and engineered immune-cell therapies. Management expects substantial increases in research, manufacturing, regulatory and public-company expenses as programs advance. It has not provided product-sales guidance or a profitability timetable.
Key risks include the absence of clinical-stage programs; uncertainty regarding safety, off-target editing, immunogenicity and long-term effects of genome editing; evolving regulatory standards; manufacturing and delivery challenges involving LNPs, AAV and complex editing components; reliance on Moderna, Ionis and Affini-T; dependence on additional financing; intense competition; intellectual-property challenges; possible delays in obtaining NHP models; cybersecurity and data-privacy risks; and uncertainty over reimbursement for potentially high-cost, one-time therapies.
The company reported no cybersecurity incident that materially affected, or was reasonably likely to materially affect, its business, results or financial condition. It also reported no material pending legal proceedings. Following Silicon Valley Bank’s failure, the company stated that it diversified cash deposits and had not experienced a material adverse effect, although financial-institution liquidity remains a risk.
Important facts for investors to verify
- Whether the company achieves its planned 2024 NHP studies, development-candidate selections and future IND-enabling milestones.
- Whether preclinical editing efficiency and durability translate into acceptable human safety and clinical benefit.
- The pace of operating cash burn relative to the stated runway into 2027 and the timing and terms of future financing.
- The sustainability and economic value of collaboration revenue, including remaining deferred revenue of approximately $68.0 million under Ionis, $23.7 million under Moderna and $1.7 million under Affini-T.
- The extent of partner control, termination rights, exclusivity provisions, milestone economics and royalty obligations under the Moderna, Ionis and Affini-T agreements.
- The sufficiency, validity and freedom-to-operate of the company’s patent portfolio, which included three issued U.S. patents and numerous pending U.S. and foreign applications at year-end.
- The impact of the IPO, reorganization, reverse stock split, equity compensation dilution and preferred-security conversion on post-IPO share counts and ownership.
- Whether the company can control rising R&D, facilities, manufacturing, regulatory and public-company costs while remaining dependent on collaboration and financing proceeds.